Lp-PLA2 / PLA2G7 (Protein | Antibody | cDNA Clone | ELISA Kit)

All Lp-PLA2 / PLA2G7 reagents are produced in house and quality controlled, including 4 Lp-PLA2 / PLA2G7 Antibody, 28 Lp-PLA2 / PLA2G7 Gene, 2 Lp-PLA2 / PLA2G7 Lysate, 2 Lp-PLA2 / PLA2G7 Protein, 2 Lp-PLA2 / PLA2G7 qPCR. All Lp-PLA2 / PLA2G7 reagents are ready to use.

Lp-PLA2 / PLA2G7 Protein (2)

    Lp-PLA2 / PLA2G7 Antibody (4)

      Lp-PLA2 / PLA2G7 cDNA Clone (28)


      In cloning vector

      In lentiviral vector

      Lp-PLA2 / PLA2G7 Lysate (2)

        Lp-PLA2 / PLA2G7 Background

        Platelet-activating factor acetylhydrolase, also known as 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycero-phosphocholine esterase, Group-VIIA phospholipase A2, LDL-associated phospholipase A2, PAF 2-acylhydrolase, PLA2G7 and PAFAH, is secreted protein which belongs to theAB hydrolase superfamily and Lipase family. PLA2G7 / PAFAH modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. It has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. PLA2G7 / PAFAH is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. PLA2G7 also represents an important, potentially functional candidate in the pathophysiology of coronary artery disease (CAD). Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PLA2G7 deficiency). It is a trait which is present in 27% of Japanese. It could have a significant physiologic effect in the presence of inflammatory bodily responses.

        Lp-PLA2 / PLA2G7 References

        • Stafforini D.M., et al., 1996, J. Clin. Invest. 97:2784-2791.
        • Yoshida H., et al., 1998, Thromb. Haemost. 80:372-375.
        • Yamada Y., et al., 1998, Metabolism 47:177-181.
        • Kruse S., et al., 2000, Am. J. Hum. Genet. 66:1522-1530.